Imeglimin: Difference between revisions

Imeglimin
Clinical data
Trade names	Twymeeg
ATC code	A10BX15 (WHO) ;
Legal status
Legal status	Rx-only in Japan;
Identifiers
	IUPAC name (2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine;
CAS Number	775351-65-0;
PubChem CID	24812808;
ChemSpider	26232690;
UNII	UU226QGU97;
CompTox Dashboard (EPA)	DTXSID50228237 ;
Chemical and physical data
Formula	C6H13N5
Molar mass	155.205 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1NC(=NC(=N1)N)N(C)C;
	InChI InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1; Key:GFICWFZTBXUVIG-SCSAIBSYSA-N;

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 16:44, 26 September 2023

Imeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg) is an oral anti-diabetic medication.^[1]^[2] It was approved for use in Japan in June 2021.^[3]

It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It is the first approved drug of this class of anti-diabetic medication.

References

^ Vuylsteke V, Chastain LM, Maggu GA, Brown C (September 2015). "Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes". Drugs in R&D. 15 (3): 227–32. doi:10.1007/s40268-015-0099-3. PMC 4561051. PMID 26254210.
^ Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K (April 2021). "Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial". Diabetes Care. 44 (4): 952–959. doi:10.2337/dc20-0763. PMID 33574125.
^ Poxel SA (June 23, 2021). "Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan" (Press release).

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[1] Vuylsteke V, Chastain LM, Maggu GA, Brown C (September 2015). "Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes". Drugs in R&D. 15 (3): 227–32. doi:10.1007/s40268-015-0099-3. PMC 4561051. PMID 26254210.

[2] Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K (April 2021). "Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial". Diabetes Care. 44 (4): 952–959. doi:10.2337/dc20-0763. PMID 33574125.

[3] Poxel SA (June 23, 2021). "Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan" (Press release).

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
+{{short description|Chemical compound}}
-'''Imeglimin''' is a drug being developed as an oral anti-diabetic. It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion.
+{{Infobox drug
+| drug_name         =
+| INN               =
+| type              = <!-- empty -->
+| image             = Imeglimin.svg
+| width             = 150px
+| alt               =
+| caption           =
+<!-- Clinical data -->
+| pronounce         =
+| tradename         = Twymeeg
+| Drugs.com         =
+| MedlinePlus       =
+| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_AU_comment =
+| pregnancy_category=
+| routes_of_administration =
+| ATCvet            =
+| ATC_prefix        = A10
+| ATC_suffix        = BX15
+<!-- Legal status -->
+| legal_AU          = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
+| legal_AU_comment  =
+| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
+| legal_BR_comment  =
+| legal_CA          = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
+| legal_CA_comment  =
+| legal_DE          = <!-- Anlage I, II, III or Unscheduled -->
+| legal_DE_comment  =
+| legal_NZ          = <!-- Class A, B, C -->
+| legal_NZ_comment  =
+| legal_UK          = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
+| legal_UK_comment  =
+| legal_US          = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
+| legal_US_comment  =
+| legal_EU          =
+| legal_EU_comment  =
+| legal_UN          = <!-- N I, II, III, IV / P I, II, III, IV -->
+| legal_UN_comment  =
+| legal_status      = Rx-only in Japan
+<!-- Pharmacokinetic data -->
+| bioavailability   =
+| protein_bound     =
+| metabolism        =
+| metabolites       =
+| onset             =
+| elimination_half-life =
+| duration_of_action=
+| excretion         =
+<!-- Identifiers -->
+| CAS_number        = 775351-65-0
+| PubChem           = 24812808
+| UNII              = UU226QGU97
+| ChemSpiderID      = 26232690
+| DrugBank          =
+<!-- Chemical and physical data -->
+| IUPAC_name        = (2''S'')-''N''<sup>6</sup>,''N''<sup>6</sup>,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
+| C=6 | H=13 | N=5
+| SMILES            = C[C@H]1NC(=NC(=N1)N)N(C)C
+| StdInChI          = 1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
+| StdInChIKey       = GFICWFZTBXUVIG-SCSAIBSYSA-N
+}}
+'''Imeglimin''' (EMD- 387008,PXL- 008,RVT-1501, brand name '''Twymeeg''') is an oral [[anti-diabetic]] medication.<ref>{{cite journal | vauthors = Vuylsteke V, Chastain LM, Maggu GA, Brown C | title = Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes | journal = Drugs in R&D | volume = 15 | issue = 3 | pages = 227–32 | date = September 2015 | pmid = 26254210 | pmc = 4561051 | doi = 10.1007/s40268-015-0099-3 }}</ref><ref>{{cite journal | vauthors = Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K | title = Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial | journal = Diabetes Care | volume = 44 | issue = 4 | pages = 952–959 | date = April 2021 | pmid = 33574125 | doi = 10.2337/dc20-0763 | doi-access = free }}</ref>  It was approved for use in Japan in June 2021.<ref>{{cite press release | title =  Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan | url = https://www.businesswire.com/news/home/20210622006160/en/Poxel-and-Sumitomo-Dainippon-Pharma-Announce-the-Approval-of-TWYMEEG%C2%AE-Imeglimin-hydrochloride-for-the-Treatment-of-Type-2-Diabetes-in-Japan | author = Poxel SA | date = June 23, 2021 }}</ref>
-Imeglimin is in development (phase IIa clinical trials) for use both as monotherapy and in combination with other diabetes treatments.<ref>https://www.genengnews.com/gen-news-highlights/diabetes-therapy-company-poxel-raises-21m-in-series-a-financing/81243635/</ref>
+It is an [[oxidative phosphorylation]] blocker that acts to inhibit hepatic [[gluconeogenesis]], increase muscle [[glucose]] uptake, and restore normal insulin secretion. It is the [[First-in-class medication|first approved drug of this class]] of anti-diabetic medication.
-==Mechanism==
-Imeglimin is mainly an indirect activator of [[AMP-activated protein kinase|AMP-kinase]].<!-- Temporary till results published --><ref>https://www.poxel.com/product-pipeline/imeglimin </ref>
-==References==
+== References ==
 {{reflist}}
+{{Oral_hypoglycemics}}
-{{pharma-stub}}
+[[Category:Anti-diabetic drugs]]
+{{gastrointestinal-drug-stub}}